<p>Coya Therapeutics, Inc.（纳斯达克代码：COYA - 获取免费报告）目前被六家覆盖该股票的券商评定为 “适度买入”，MarketBeat.com 报道。一位分析师给予该股票卖出评级，五位分析师则对该公司给予买入评级。在过去一年中，给予该股票评级的券商的平均 12 个月目标价为 16.00 美元。</p>
<p>获取 <strong>Coya Therapeutics</strong> 的提醒：</p>
<ul>
<li>你在做假日购物吗？这些股票可能是很好的礼物</li>
</ul>
<p>多家研究公司最近对 COYA 发表了看法。D. Boral Capital 在周一的报告中重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 15.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了 Coya Therapeutics 的 “卖出（d-）” 评级。HC Wainwright 在 11 月 24 日的报告中重申了 Coya Therapeutics 的 “买入” 评级。Chardan Capital 在 11 月 14 日的研究报告中重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 14.00 美元。最后，华尔街禅在 11 月 15 日的报告中将 Coya Therapeutics 的评级从 “卖出” 上调至 “持有”。</p>
<p><strong>查看我们最新的 COYA 股票报告</strong></p>
<h2>Coya Therapeutics 股票下跌 1.9%</h2>
<ul>
<li>这些生物技术公司针对多种神经退行性疾病</li>
</ul>
<p>COYA 股票在周四开盘价为 5.15 美元。该公司的 50 日移动平均价格为 5.86 美元，200 日移动平均价格为 6.05 美元。该股票的市值为 1.0774 亿美元，市盈率为-4.64，贝塔值为 0.25。Coya Therapeutics 的 12 个月低点为 4.65 美元，12 个月高点为 8.29 美元。</p>
<p>Coya Therapeutics（纳斯达克代码：COYA - 获取免费报告）最近在 11 月 12 日发布了季度财报。该公司报告每股收益为（0.10 美元），低于共识预期的 0.02 美元，差距为（0.12 美元）。Coya Therapeutics 的股本回报率为-55.76%，净利润率为-462.24%。该公司本季度的收入为 356 万美元，而共识预期为 370 万美元。股票研究分析师预计 Coya Therapeutics 在当前财政年度将发布-1.15 的每股收益。</p>
<h2>Coya Therapeutics 的机构交易</h2>
<p>多家对冲基金和其他机构投资者最近调整了对该股票的持有。摩根大通在第三季度购买了 Coya Therapeutics 的新头寸，价值约 28,000 美元。Lantern Wealth Advisors LLC 在第三季度收购了 Coya Therapeutics 的新股份，价值 66,000 美元。西北互助财富管理公司在第二季度购买了 Coya Therapeutics 的新股份，价值 119,000 美元。Prosperity Wealth Management Inc. 在第三季度将其在 Coya Therapeutics 的持股增加了 16.4%。Prosperity Wealth Management Inc. 现在拥有该公司 23,800 股股票，价值 136,000 美元，此前在上个季度又收购了 3,350 股。最后，Jane Street Group LLC 在第一季度将其在 Coya Therapeutics 的持股增加了 101.7%。Jane Street Group LLC 现在拥有该公司 26,137 股股票，价值 169,000 美元，此前在上个季度又收购了 13,176 股。机构投资者和对冲基金持有该公司 39.75% 的股票。</p>
<h2>关于 Coya Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Coya Therapeutics, Inc.（纳斯达克代码：COYA）是一家临床阶段的生物技术公司，专注于针对纤维化疾病和癌症的首创治疗药物的发现和开发。该公司的科学方法集中在靶向 UNC-45A，这是一种参与细胞运动、增殖和细胞外基质沉积调节的分子伴侣。通过调节 UNC-45A 的活性，Coya 旨在解决目前缺乏有效治疗的组织纤维化和肿瘤进展的潜在机制。</p>
<p>Coya 的产品管线以两个主要项目为基础：COY-001，一种针对特发性肺纤维化和系统性硬化症等纤维化疾病的临床前小分子抑制剂，以及 COY-002，正在向临床推进，针对某些实体肿瘤。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Coya Therapeutics</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09ZQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09ZQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Coya Therapeutics 吗？</h2>
<p>在你考虑 Coya Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Coya Therapeutics 并不在名单上。</p>
<p>虽然 Coya Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

COYA

<p>Coya Therapeutics, Inc.（纳斯达克代码：COYA）获得了六家券商的 “适度买入” 共识评级。一位分析师将其评级为卖出，而五位分析师则给予买入评级。12 个月的平均目标价为 16.00 美元。该股票开盘价为 5.15 美元，市值为 1.0774 亿美元。Coya 报告的季度每股亏损为（0.10 美元），未能达到预期。机构投资者持有该股票的 39.75%。Coya 专注于开发针对纤维化疾病和癌症的治疗药物，目前有两个主要项目处于临床前和临床阶段</p>

<p>Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned a consensus rating of &#34;Moderate Buy&#34; from the six brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $16.00.</p>
<div class="lb-trans"><p>Coya Therapeutics, Inc.（纳斯达克代码：COYA - 获取免费报告）目前被六家覆盖该股票的券商评定为 “适度买入”，MarketBeat.com 报道。一位分析师给予该股票卖出评级，五位分析师则对该公司给予买入评级。在过去一年中，给予该股票评级的券商的平均 12 个月目标价为 16.00 美元。</p>
</div><p>Get <strong>Coya Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Coya Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Doing Your Holiday Shopping? These Stocks Might Make Great Gifts</li>
</ul>
<div class="lb-trans"><ul>
<li>你在做假日购物吗？这些股票可能是很好的礼物</li>
</ul>
</div><p>A number of research firms recently weighed in on COYA. D. Boral Capital reaffirmed a &#34;buy&#34; rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Monday. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a &#34;buy&#34; rating on shares of Coya Therapeutics in a report on Monday, November 24th. Chardan Capital reiterated a &#34;buy&#34; rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Friday, November 14th. Finally, Wall Street Zen raised shares of Coya Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 15th.</p>
<div class="lb-trans"><p>多家研究公司最近对 COYA 发表了看法。D. Boral Capital 在周一的报告中重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 15.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了 Coya Therapeutics 的 “卖出（d-）” 评级。HC Wainwright 在 11 月 24 日的报告中重申了 Coya Therapeutics 的 “买入” 评级。Chardan Capital 在 11 月 14 日的研究报告中重申了 “买入” 评级，并将 Coya Therapeutics 的目标价设定为 14.00 美元。最后，华尔街禅在 11 月 15 日的报告中将 Coya Therapeutics 的评级从 “卖出” 上调至 “持有”。</p>
</div><p><strong>Check Out Our Latest Stock Report on COYA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 COYA 股票报告</strong></p>
</div><h2>Coya Therapeutics Stock Down 1.9%</h2>
<div class="lb-trans"><h2>Coya Therapeutics 股票下跌 1.9%</h2>
</div><ul>
<li>These biotechs targeting multiple neurodegenerative diseases</li>
</ul>
<div class="lb-trans"><ul>
<li>这些生物技术公司针对多种神经退行性疾病</li>
</ul>
</div><p>Shares of COYA opened at $5.15 on Thursday. The company has a 50-day moving average price of $5.86 and a two-hundred day moving average price of $6.05. The stock has a market cap of $107.74 million, a price-to-earnings ratio of -4.64 and a beta of 0.25. Coya Therapeutics has a 12 month low of $4.65 and a 12 month high of $8.29.</p>
<div class="lb-trans"><p>COYA 股票在周四开盘价为 5.15 美元。该公司的 50 日移动平均价格为 5.86 美元，200 日移动平均价格为 6.05 美元。该股票的市值为 1.0774 亿美元，市盈率为-4.64，贝塔值为 0.25。Coya Therapeutics 的 12 个月低点为 4.65 美元，12 个月高点为 8.29 美元。</p>
</div><p>Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $3.70 million. Equities research analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Coya Therapeutics（纳斯达克代码：COYA - 获取免费报告）最近在 11 月 12 日发布了季度财报。该公司报告每股收益为（0.10 美元），低于共识预期的 0.02 美元，差距为（0.12 美元）。Coya Therapeutics 的股本回报率为-55.76%，净利润率为-462.24%。该公司本季度的收入为 356 万美元，而共识预期为 370 万美元。股票研究分析师预计 Coya Therapeutics 在当前财政年度将发布-1.15 的每股收益。</p>
</div><h2>Institutional Trading of Coya Therapeutics</h2>
<div class="lb-trans"><h2>Coya Therapeutics 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase &amp; Co. bought a new position in Coya Therapeutics in the 3rd quarter worth approximately $28,000. Lantern Wealth Advisors LLC acquired a new stake in shares of Coya Therapeutics in the 3rd quarter valued at $66,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Coya Therapeutics during the second quarter worth $119,000. Prosperity Wealth Management Inc. raised its position in shares of Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company's stock worth $136,000 after acquiring an additional 3,350 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock worth $169,000 after acquiring an additional 13,176 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company's stock.</p>
<div class="lb-trans"><p>多家对冲基金和其他机构投资者最近调整了对该股票的持有。摩根大通在第三季度购买了 Coya Therapeutics 的新头寸，价值约 28,000 美元。Lantern Wealth Advisors LLC 在第三季度收购了 Coya Therapeutics 的新股份，价值 66,000 美元。西北互助财富管理公司在第二季度购买了 Coya Therapeutics 的新股份，价值 119,000 美元。Prosperity Wealth Management Inc. 在第三季度将其在 Coya Therapeutics 的持股增加了 16.4%。Prosperity Wealth Management Inc. 现在拥有该公司 23,800 股股票，价值 136,000 美元，此前在上个季度又收购了 3,350 股。最后，Jane Street Group LLC 在第一季度将其在 Coya Therapeutics 的持股增加了 101.7%。Jane Street Group LLC 现在拥有该公司 26,137 股股票，价值 169,000 美元，此前在上个季度又收购了 13,176 股。机构投资者和对冲基金持有该公司 39.75% 的股票。</p>
</div><h2>About Coya Therapeutics</h2>
<div class="lb-trans"><h2>关于 Coya Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.</p>
<div class="lb-trans"><p>Coya Therapeutics, Inc.（纳斯达克代码：COYA）是一家临床阶段的生物技术公司，专注于针对纤维化疾病和癌症的首创治疗药物的发现和开发。该公司的科学方法集中在靶向 UNC-45A，这是一种参与细胞运动、增殖和细胞外基质沉积调节的分子伴侣。通过调节 UNC-45A 的活性，Coya 旨在解决目前缺乏有效治疗的组织纤维化和肿瘤进展的潜在机制。</p>
</div><p>Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.</p>
<div class="lb-trans"><p>Coya 的产品管线以两个主要项目为基础：COY-001，一种针对特发性肺纤维化和系统性硬化症等纤维化疾病的临床前小分子抑制剂，以及 COY-002，正在向临床推进，针对某些实体肿瘤。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Coya Therapeutics</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>A month before the crash</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Coya Therapeutics</li>
<li>你还认为白银是个笑话吗？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09ZQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=COYA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Coya Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Coya Therapeutics 吗？</h2>
</div><p>Before you consider Coya Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Coya Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Coya Therapeutics 并不在名单上。</p>
</div><p>While Coya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Coya Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Coya Therapeutics, Inc.（纳斯达克股票代码：COYA）被券商一致评为 “适度买入”